clinical outcomes are poor for cll patients treated with venetoclax post-btki exposure
Published 5 months ago • 352 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
5:45
treatment effectiveness of venetoclax-based therapy after btki exposure in cll/sll
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
1:39
retreatment with a btki plus venetoclax after relapse is effective in cll: insights from captivate
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:04
time-limited venetoclax-rituximab in r/r cll patients previously exposed to btki’s
-
1:12
patients with cll on continuous ibrutinib have a life expectancy comparable to healthy individuals
-
3:08
recent updates on tp53 mutation in cll
-
4:19
cll: what is 'watch & wait' and what can a patient do during this phase?
-
1:42
treating cll after venetoclax or btk inhibitors
-
3:33
investigating the safety and efficacy of re-treating cll patients with venetoclax-based regimens
-
1:18
involving the patient in treatment decisions for cll
-
2:43
treatment sequencing options for recurrent cll
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
0:49
venice ii trial: health-related qol in patients with cll treated with venetoclax
-
2:08
an insight into the current understanding of risk factors for cll
-
1:12
insights into the optimal management of cll: the importance of patient characteristics
-
1:18
the impact of the approval of pirtobrutinib on the treatment landscape for patients with cll
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
1:11
telomere dysfunction to predict clinical outcomes in cll
-
1:17
an ongoing phase i/ii study of sonrotoclax zanubrutinib in patients with treatment-naive cll/sll